ODYSSEY OUTCOMES: Update
New data from FOURIER and design of the VESALIUS-CV Trial
PCSK9 Genetics: New Insights
Jan Boren Hepatic lipid metabolism: Storage vs secretion
Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins
Erik Stroes New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations
Frederick J. Raal Inclisiran: The Phase 3 trial
Peter Sever FOURIER trial: Update on subgroup analyses
Andreas M Zeiher ODYSSEY OUTCOMES: Update
Henry Ginsberg The new AHA/ACC Treatment Guidelines: Critical appraisal
Børge Nordestgaard Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?
Gregory G. Schwartz Michael Szarek ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)
Erin Bohula Lp(a) and CV risk: Insights from the FOURIER trial
Anne Tybjaerg-Hansen Genetics of Lp(a) and CVD
John Chapman Do LDL subfractions matter?
Bo Angelin PCSK9 and the adrenals: how are cholesterol levels protected?
Gerard Pasterkamp Does one plaque characteristic fit all?
Pia Kamstrup Lp(a) as a cardiovascular risk factor – Is lowering Lp(a) beneficial when LDL is low?
Francois Mach Low LDL-C and cognitive function: Benefit or harm?
Dirk Müller-Wieland Do low LDL-C levels enhance diabetes risk?